Hydromorphone intranasal

Drug Profile

Hydromorphone intranasal

Alternative Names: Intranasal hydromorphone HCl

Latest Information Update: 29 Aug 2011

Price : $50

At a glance

  • Originator Intranasal Therapeutics
  • Developer Ikano Therapeutics
  • Class Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 22 Aug 2005 Intranasal Technology is now called Intranasal Therapeutics
  • 24 Aug 2004 Phase-II clinical trials in Pain in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top